Formalizing an integrative, multidisciplinary cancer therapy discovery workflow

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6111-6117

  McGuire, Mary F ^a   Enderling, Heiko ^b,i   Wallace, Dorothy I ^d   Batra, Jaspreet ^b   Jordan, Marie ^c   Kumar, Sushil ^f   Panetta, John C ^e   Pasquier, Eddy ^g,h  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Boston University   (United States)

^d Lamont Doherty Earth Observatory   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h Metronomics Global Health Initiative   (France)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MELPHALAN; METFORMIN; NIFURTIMOX; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOIC ACID; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL SIMULATION; COMPUTER MODEL; CONCEPTUAL FRAMEWORK; DRUG DEVELOPMENT; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; INTERDISCIPLINARY RESEARCH; MAINTENANCE THERAPY; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SIMULATION; TEAMWORK; TUMOR GROWTH; WORKFLOW;

CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; WORKFLOW;

EID: 84886069496     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0310     Document Type: Review

References (50)

1. Hahnfeldt P, Hlatky L, Klement GL Center of cancer systems biology second annual workshop-tumor metronomics: timing and dose level dynamics. Cancer Res 2013; 73:2949-54.
2. Nathan DG. The several Cs of translational clinical research. J Clin Invest 2005; 115:795-7.
3. Payne PR, Borlawsky TB, Kwok A, Greaves AW Supporting the design of translational clinical studies through the generation and verification of conceptual knowledge-anchored hypotheses. AMIA Annu Symp Proc 2008:566-70.
4. Holford N, Ma SC, Ploeger BA Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88:166-82.
5. Best A, Hiatt RA, Cameron R, Rimer B.K., Abrams DB The evolution of cancer control research: an international perspective from Canada and the United States. Cancer Epidemiol Biomarkers Prev 2003; 12: 705-12.
6. IOM. Barriers to interdisciplinary research and training. In: Pellmar TC, Eisenberg L, editors. Bridging disciplines in the brain, behavioral, and clinical sciences. Washington, DC: The National Academies; 2000. p. 41-57.
7. IOM. Facilitating collaborations to develop combination investigational cancer therapies: workshop summary. Washington, DC: The National Academies Press; 2012.
8. Mittra J, Tait J. Analysing stratified medicine business models and value systems: innovation-regulation interactions. New Biotechnol 2012; 29:709-19.
9. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-65.
10. Andre N, Abed S, Orbach D., Alla CA, Padovani L, Pasquier E, et al Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011; 2: 960-5.
11. Beukers MW. Project management of life-science research projects: project characteristics, challenges and training needs. Drug Discov Today 2011; 16:93-8.
12. Milton JG, Radunskaya AE, Lee A.H., de Pillis LG, Bartlett DF Team research at the biology-mathematics interface: project management perspectives. CBE Life Sci Educ 2010; 9:316-22.
13. PMI. A guide to the Project Management Body of Knowledge (PMBOK Guide). Newtown Square, PA: Project Management Institute, Inc.; 2008.
14. Sodeke S, Turner T, Tarver W. The ethics of good communication in a complex research partnership. J Health Care Poor Underserved 2010; 21:35-45.
15. Brown RE, McGuire MF Oncogenesis recapitulates embryogenesis via the hypoxia pathway: morphoproteomics and biomedical analytics provide proof of concept and therapeutic options. Ann Clin Lab Sci 2012; 42:243-57.
16. McGuire MF, Iyengar MS, Mercer DW Computational approaches for translational clinical research in disease progression. J Invest Med 2011; 59:893-903.
17. McGuire MF, Iyengar MS, Mercer DW Data driven linear algebraic methods for analysis of molecular pathways: application to disease progression in shock/trauma. J Biomed Inform 2012; 45:372-87.
18. Fardin P, Barla A, Mosci S., Rosasco L, Verri A, Versteeg R., et al A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 2010; 9:185.
19. Sherar MD, Noss MB, Foster FS Ultrasound backscatter microscopy images the internal structure of living tumour spheroids. Nature 1987; 330:493-5.
20. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
21. Freyer JP. Role of necrosis in regulating the growth saturation of multicellular spheroids. Cancer Res 1988; 48:2432-9.
22. Johnsen JI, Lindskog M, Ponthan F., Pettersen I, Elfman L, Orrego A., et al NSAIDs in neuroblastoma therapy. Cancer Lett 2005; 228: 195-201.
23. Saulnier Sholler G.L., Bergendahl GM, Brard L, Singh A.P., Heath BW, Bingham PM, et al A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 2011; 33: 25-30.
24. Dowling RJ, Niraula S, Stambolic V., Goodwin PJ Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48: R31-43.
25. Gonyeau MJ, Yuen DW A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy 2010; 30:177-94.
26. Pasquier E, Street J, Pouchy C., Carre M, Gifford AJ, Murray J, et al β-Blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer 2013; 108:2485-94.
27. Francia G, Cruz-Munoz W, Man S., Xu P, Kerbel RS Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011; 11:135-41.
28. Tentler JJ, Tan AC, Weekes C.D., Jimeno A., Leong S, Pitts TM, et al Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9:338-50.
29. Nguyen LV, Vanner R, Dirks P., Eaves CJ Cancer stem cells: an evolving concept. Nat Rev Cancer 2012; 12:133-43.
30. Weiss WA, Aldape K, Mohapatra G., Feuerstein BG, Bishop JM Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16:2985-95.
31. Li Y, Nguyen MH, Cheng S, Schmidt S., Zhong L, Derendorf H, et al A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents 2008; 31:369-74.
32. Pery AR, Brochot C, Zeman F.A., Mombelli E., Desmots S, Pavan M, et al Prediction of dose-hepatotoxic response in humans based on toxicokinetic/ toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. Toxicol Lett 2013; 220: 26-34.
33. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61:275-91.
34. Manolis E, Osman TE, Herold R, Koenig F., Tomasi P, Vamvakas S, et al Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth 2011; 21:214-21.
35. Simulation for Designing Clinical Trials: a pharmacokinetic- pharmacodynamic modeling perspective. New York, NY: Marcel Dekker; 2003.
36. Miller R, Ewy W, Corrigan B.W., Ouellet D., Hermann D, Kowalski KG, et al How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005; 32: 185-97.
37. Gobburu JV, Marroum PJ Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001; 40:883-92.
38. Wang Y, Bhattaram AV, Jadhav P.R., Lesko LJ, Madabushi R, Powell JR, et al Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol 2008; 48:146-56.
39. Boessen R, Knol MJ, Groenwold R.H., Roes KC Validation and predictive performance assessment of clinical trial simulation models. Clin Pharmacol Ther 2011; 89:487-8; author reply 8.
40. Holford N, Ma SC, Ploeger BA Response to validation and assessment of predictive performance in simulation models of clinical trials. Clin Pharmacol Ther 2011; 89:488.
41. Panetta JC, Schaiquevich P, Santana V.M., Stewart CF Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res 2008; 14:318-25.
42. Cantley LC, Dalton WS, DuBois R.N., Finn OJ, Futreal PA, Golub TR, et al AACR Cancer Progress Report 2012. Clin Cancer Res 2012; 18: S1-100.
43. Swierniak A, Kimmel M, Smieja J. Mathematical modeling as a tool for planning anticancer therapy. Eur J Pharmacol 2009; 625:108-21.
44. Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer 2010; 10:221-30.
45. Wallace DI, Winsor P. Sensitive dependence on the threshold for TAF signaling in solid tumors. In: Mondaini R, editor. BIOMAT 2011. Hackensack, NJ: World Scientific Publishing; 2011. p. 264-78.
46. Peyrl A, Chocholous M, Kieran M.W., Azizi AA, Prucker C, Czech T, et al Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012; 59:511-7.
47. Kieran MW, Turner CD, Rubin J.B., Chi SN, Zimmerman MA, Chordas C, et al A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005; 27:573-81.
48. Panigrahy D, Kaipainen A, Butterfield C.E., Chaponis DM, Laforme AM, Folkman J, Kieran MW Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med 2010; 1:739-46.
49. Robison N, Campigotta F, Chi S., Manley P, Turner C, Zimmerman M.A., et al A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 2011; 57:815.
50. Lowenstein PR, Castro MG Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther 2009; 9:368-74.